SpinaFX Medical receives FDA Investigational Device Exemption (IDE) for Triojection®, its Breakthrough, Minimally-Invasive, Image-Guided Lumbar Disc Treatment. (opens in new tab)

The prospective, randomized, multicenter trial will compare intradiscal ozone/oxygen injection plus nerve root block to nerve root block alone in 300 patients in up to 30 US sites TORONTO, June 9, 2026 /PRNewswire/ – SpinaFX Medical, a clinical-stage medical device company specializing in minimally invasive, image-guided therapies for intravertebral disc disorders, today announced that the U.S. Food […] The post appeared first on <a href="